Warning: The NCBI web site requires JavaScript to function. more...
Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin.
Colditz GA.
Breast Cancer Res. 2007;9(4):108. Erratum in: Breast Cancer Res. 2007;9(6):401.
Related citations
Estrogen, estrogen plus progestin therapy, and risk of breast cancer.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):909s-17s. Review.
Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
Glass AG, Lacey JV Jr, Carreon JD, Hoover RN.
J Natl Cancer Inst. 2007 Aug 1;99(15):1152-61. Epub 2007 Jul 24.
Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA.
J Clin Oncol. 2003 Dec 1;21(23):4314-21.
Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
Nozaki M, Koera K, Nagata H, Nakano H.
J Obstet Gynaecol Res. 2004 Aug;30(4):297-302.
Re: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
Kuller LH.
J Natl Cancer Inst. 2000 Jul 5;92(13):1100-1. No abstract available.
Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.
Speroff L.
Menopause. 2008 Mar-Apr;15(2):393-400. Review.
Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer.
Jick SS, Hagberg KW, Kaye JA, Jick H.
Obstet Gynecol. 2009 Jan;113(1):74-80.
Estrogen plus progestin and risk of benign proliferative breast disease.
Rohan TE, Negassa A, Chlebowski RT, Lasser NL, McTiernan A, Schenken RS, Ginsberg M, Wassertheil-Smoller S, Page DL.
Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2337-43. Epub 2008 Aug 25.
Postmenopausal hormone therapy and breast cancer.
[No authors listed]
Prescrire Int. 2009 Apr;18(100):66-7.
Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada.
Kirsh V, Kreiger N.
Cancer Causes Control. 2002 Aug;13(6):583-90.
Hormones and breast cancer: evidence and implications for consideration of risks and benefits of hormone replacement therapy.
J Womens Health. 1999 Apr;8(3):347-57. Review.
Hormone replacement therapy in women with breast cancer.
Braendle W.
Anticancer Res. 1998 May-Jun;18(3C):2253-5. Review.
Re: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
Archer DF, Bush T, Nachtigall LE.
J Natl Cancer Inst. 2000 Dec 6;92(23):1950-2. No abstract available.
Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
Lacey JV Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C.
Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1724-31.
Neoplasia of the female reproductive tract: effects of hormone therapy.
Archer DF.
Endocrine. 2004 Aug;24(3):259-63. Review.
Breast cancer and hormone replacement therapy: putting the risk into perspective.
Campagnoli C, Abbà C, Ambroggio S, Biglia N, Ponzone R.
Gynecol Endocrinol. 2001 Dec;15 Suppl 6:53-60. Review.
Estrogen-progestin increases breast cancer risk.
Stephens MB.
J Fam Pract. 2000 Apr;49(4):301-2. No abstract available.
Breast cancer and hormone-replacement therapy: the Million Women Study.
Garton M.
Lancet. 2003 Oct 18;362(9392):1328; author reply 1330-1. No abstract available.
More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
Magnusson C, Persson I, Adami HO.
J Natl Cancer Inst. 2000 Jul 19;92(14):1183-4. No abstract available.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on